Comparison of the cost of direct acting antiviral drugs interferon-based therapy in liver transplant patients with relapse of HCV infection

Kliknij autora aby wyszukać wszystkie publikowane przez niego artykuły:
Karolina Hawryluk, Michał Ciszek

4 (61) 2019 s. 326–330
Click to return to issue contents
326_4_61_2019.pdf
Digital version of article (in PDF file)

DOI: https://doi.org/10.20883/ppnoz.2019.65

Fraza do cytowania: Hawryluk K., Ciszek M. Comparison of the cost of direct acting antiviral drugs interferon-based therapy in liver transplant patients with relapse of HCV infection. Polski Przegląd Nauk o Zdrowiu. 2019;4(61):326–330. DOI: https://doi.org/10.20883/ppnoz.2019.65

Hepatitis C (Hepatitis C) is the most common cause of liver cirrhosis and hepatocellular carcinoma. Until recently, long-lasting treatment with interferon alfa and ribavirin was the only available therapeutic option. The therapy was ineffective in many cases, especially in liver transplant patients and caused many side effects. New treatment regimens based on drugs with direct action on the virus are characterized by high efficacy, shorter treatment time and very rare occurrence of side effects. The aim of the study was to compare the total costs of treatment with both types of therapy in patients with chronic hepatitis C after liver transplantation. The paper summarizes the costs of drugs in the program and additional drugs, diagnostics procedures, outpatient visits and hospitalizations. Based on the performed analysis, it appears that the total cost of interferon and non-interferon therapy for the studied group of patients is comparable.

Key words: HCV, DAA, interferon, treatment costs.



Copyright © 1989–2024 Polish Review of Health Sciences. All rights reserved.